CymaBay Therapeutics

147 articles about CymaBay Therapeutics

• CymaBay Therapeutics Presents Positive PBC Data at the International Liver Congress™ 2022

  6/22/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced encouraging seladelpar data in patients with primary biliary cholangitis (PBC) that are being presented at The International Liver Congress™ 2022.

• CymaBay Therapeutics Presents New Findings that Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

  5/23/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that results from new analyses of clinical studies of seladelpar were presented during Digestive Disease Week® (DDW) .

• CymaBay Reports First Quarter 2022 Financial Results and Provides Corporate Update

  5/12/2022

  CymaBay Therapeutics, Inc. announced corporate updates and financial results for the first quarter ended March 31, 2022.

• CymaBay Therapeutics Announces Presentations at Digestive Disease Week® 2022Seladelpar Phase 2 Study Selected for DDW Presidential Plenary Session

  5/11/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple Phase 2 and Phase 3 study presentations on seladelpar, the first delpar currently in development for the treatment of PBC, will be delivered during Digestive Disease Week® (DDW) May 21 – 24.

• CymaBay Therapeutics to Report First Quarter of 2022 Financial Results on Thursday, May 12, 2022

  5/5/2022

  CymaBay Therapeutics, Inc. announced that it will host a conference call and live audio webcast on Thursday, May 12, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the first quarter ended March 31, 2022 and to provide a business update.

• 

  Clinical Catch-Up: COVID-19, AAN, ACC

  4/11/2022

  It was a very busy week for clinical trial news, in part because of presentations coming out of the American Academy of Neurology (AAN) meeting. Here’s a look.

• CymaBay Therapeutics Announces Publication of Results From a 52-Week, Open-Label, Phase 2 Study of Seladelpar in Patients With Primary Biliary Cholangitis

  4/4/2022

  CymaBay Therapeutics, Inc. today announced that results from the Phase 2, 52-week study of seladelpar in patients with primary biliary cholangitis (PBC) have been published in the Journal of Hepatology.

• CymaBay Reports Fourth Quarter and Year Ended December 31, 2021 Financial Results and Provides Corporate Update

  3/17/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced corporate updates and financial results for the fourth quarter and fiscal year ended December 31, 2021.

• CymaBay Announces Appointment of Éric Lefebvre, M.D. to Board of Directors

  3/17/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced the appointment of Dr. Éric Lefebvre to its Board of Directors.

• CymaBay Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 17, 2022

  3/10/2022

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, today announced that it will host a conference call and live audio webcast on Thursday, March 17, 2022 at 4:30 p.m. Eastern Time to discuss financial results for the fourth quarter and year ended December 31, 2021 and to provide a business update.

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Feb 10, 2022

  2/10/2022

  CymaBay Therapeutics, Inc. announced that management will participate in two virtual investor conferences including the 11th Annual SVB Leerink Global Healthcare Conference taking place February 14-18, 2022 and Oppenheimer’s 32nd Annual Healthcare Conference taking place March 15-16, 2022.

• 

  After Setbacks, CymaBay Pushes Forward with Potential Liver Disease Treatment

  12/9/2021

  The holds were lifted by the FDA in July of 2020, but the company’s timeline had been severely set back by the miscalculation.

• CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

  11/18/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.

• CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

  11/17/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need, announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

• CymaBay Therapeutics Long-term Open Label Study Finds Treatment with Seladelpar for Two Years Improves Key Liver Biomarkers in Patients with PBC

  11/15/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that results of analyses from two clinical studies of seladelpar were delivered during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).

• CymaBay Therapeutics to Host Post-AASLD Key Opinion Leader Webinar on Seladelpar for Primary Biliary CholangitisWebinar on Monday, November 15th, @ 4:30pm EST

  11/11/2021

  CymaBay Therapeutics, Inc. today announced that it will host a Key Opinion Leader (KOL) webinar on seladelpar for primary biliary cholangitis (PBC) on Monday, November 15, at 4:30pm EST.

• CymaBay Reports Third Quarter and Nine Months Ended September 30, 2021 Financial Results and Provides Corporate Update

  11/10/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced corporate updates and financial results for the third quarter ended September 30, 2021.

• CymaBay Therapeutics to Present at Upcoming Investor Conferences - Nov 04, 2021

  11/4/2021

  CymaBay Therapeutics, Inc. announced that management will participate in three virtual investor conferences including the Credit Suisse 30th Annual Healthcare Conference taking place November 8-11, 2021, the Evercore ISI 4th Annual HealthCONx Conference taking place November 30 – December 2, 2021 and the Piper Sandler 33rd Annual Virtual Healthcare Conference taking place November 30 – December 2, 2021.

• CymaBay Therapeutics to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

  11/3/2021

  CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet need, announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021 at 4:30 p.m. Eastern Time to discuss financial results for the third quarter ended September 30, 2021 and to provide a business update.

• CymaBay Therapeutics Announces Presentations at The Liver Meeting® 2021

  10/1/2021

  CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases, today announced that multiple presentations of results from clinical and preclinical studies of seladelpar will be delivered during The Liver Meeting Digital Experience™ 2021 (TLMdX) of the American Association for the Study of Liver Diseases (AASLD).